In addition, several Mcl-1 inhibitors have entered clinical evaluation in patients with hematological malignancies [36], of which S64315 (MIK665) is chemically related to S63845 (used here), and has shown comparable activity [57]. The gene discussed is MCL1; the disease is hematologic disorder.